Payment overview · 2025
General Payments
$343.50
11 reported records · 8 companies
Healthcare provider profile · identity verified
Camille Nancy Anise, MD
Allopathic & Osteopathic Physicians|Family Medicine · SARASOTA, FL · NPI 1790949113
Verified facts
What the public records show
CMS Open Payments records show Camille Nancy Anise, MD received $343.50 in general payments during 2025 across 11 reported records.
Lilly USA, LLC accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $125.00 | 36.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $81.27 | 23.7% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.78 | 8.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.26 | 7.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.24 | 7.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.85 | 6.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.14 | 5.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.96 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $343.50 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.87 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.09 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $25.26 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 55 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 391 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 332 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 266 | 90 |
| Losartan Potassium | Losartan Potassium | 258 | 86 |
| Omeprazole | Omeprazole | 219 | 72 |
| Simvastatin | Simvastatin | 214 | 65 |
| Gabapentin | Gabapentin | 193 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 189 | 68 |
| Metformin Hcl | Metformin Hcl | 185 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 167 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 46 |
| Furosemide | Furosemide | 130 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 130 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 50 |
| Tramadol Hcl | Tramadol Hcl | 117 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 30 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 102 | 34 |
| Trazodone Hcl | Trazodone Hcl | 101 | 34 |
| Alendronate Sodium | Alendronate Sodium | 81 | 33 |
| Meloxicam | Meloxicam | 80 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 28 |
| Potassium Chloride | Potassium Chloride | 69 | 21 |
| Alprazolam | Alprazolam | 66 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 23 |
| Montelukast Sodium | Montelukast Sodium | 59 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | 18 |
| Ezetimibe | Ezetimibe | 56 | 18 |
| Eliquis | Apixaban | 55 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 18 |
| Glipizide | Glipizide | 55 | 20 |
| Fenofibrate | Fenofibrate | 54 | 18 |
| Buspirone Hcl | Buspirone Hcl | 53 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | 18 |
| Prednisone | Prednisone | 52 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 22 |
| Allopurinol | Allopurinol | 45 | 15 |
| Glimepiride | Glimepiride | 43 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 12 |
| Clonidine Hcl | Clonidine Hcl | 40 | 13 |
| Donepezil Hcl | Donepezil Hcl | 40 | 14 |
| Famotidine | Famotidine | 40 | 14 |
| Baclofen | Baclofen | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 12 |
| Sertraline Hcl | Sertraline Hcl | 38 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 13 |
| Lovastatin | Lovastatin | 37 | 12 |
| Carvedilol | Carvedilol | 36 | 16 |
| Warfarin Sodium | Warfarin Sodium | 34 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 18 |
| Atenolol | Atenolol | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Guanfacine Hcl | Guanfacine Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | 11 |
| Nystatin | Nystatin | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $343.50 · 11 records | Lilly USA, LLC | CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, EVENITY, GARDASIL 9, LUX-Dx Insertable Cardiac Monitor, NURTEC ODT, OTEZLA, REPATHA, TRELEGY ELLIPTA, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error